Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders - PubMed (original) (raw)

Review

doi: 10.1038/nrd4360. Epub 2014 Aug 18.

Affiliations

Review

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

Katrina J Falkenberg et al. Nat Rev Drug Discov. 2014 Sep.

Abstract

Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Nat Rev Cancer. 2006 Jan;6(1):38-51 - PubMed
    1. J Biol Chem. 2005 Jul 22;280(29):26729-34 - PubMed
    1. Nat Rev Cancer. 2011 Sep 23;11(10):726-34 - PubMed
    1. Oncogene. 2014 Nov 20;33(47):5415-23 - PubMed
    1. Oncogene. 2010 Nov 4;29(44):5957-68 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources